Early Mortality during Initial Treatment of Tuberculosis in Patients Co-Infected with HIV at the Yaoundé Central Hospital, Cameroon: An 8-Year Retrospective Cohort Study (2006-2013)

Abstract

BackgroundUnderstanding contributors to mortality during the initial phase of tuberculosis (TB) treatment in patients co-infected with HIV would guide targeted interventions to improve survival. The aim of this study was to ascertain the incidence of death during the initial 2 months (new cases) and 3 months (retreatment cases) of TB treatment and to assess correlates of mortality in HIV co-infected patients.MethodsWe conducted a hospital-based retrospective cohort study from January 2006 to December 2013 at Yaoundé Central Hospital, Cameroon. We reviewed medical records to identify co-infected TB/HIV inpatients aged 15 years and older who died during TB treatment. Death was defined as any death occurring during TB treatment, as per World Health Organization recommendations. We collected socio-demographic, clinical and laboratory data. We conducted multivariable logistic binary regression analysis to identify factors associated with death during the intensive phase of TB treatment. Magnitudes of associations were expressed by adjusted odds ratio (aOR) with 95% confidence interval. A p value < 0.05 was considered statistically significant.ResultsThe 99 patients enrolled had a mean age of 39.5 (standard deviation 10.9) years and 53% were male. Patients were followed for 276.3 person-months of observation (PMO). Forty nine patients were died during intensive phase of TB treatment. Death incidence during the intensive phase of TB treatment was 32.2 per 100 PMO. Having a non-AIDS comorbidity (aOR 2.47, 95%CI 1.22-5.02, p = 0.012), having extra-pulmonary TB (aOR 1.89, 95%CI 1.05-3.43, p = 0.035), and one year increase in duration of known HIV infection (aOR 1.23, 95%CI 1.004-1.49) were independently associated with death during the intensive phase of TB treatment.ConclusionsMortality incidence during intensive phase of TB treatment was high among TB/HIV co-infected patients during TB treatment; and strongly associated with extra pulmonary TB suggesting advanced stage of immunosuppression and non-AIDS comorbidities. Early HIV diagnosis and care and good management of non-comorbidities can reduce this incidence.

Home-Based and Facility-Based Directly Observed Therapy of Tuberculosis Treatment under Programmatic Conditions in Urban Tanzania

“…Future research should focus on developing simple risk assessment tools based on evidence from prospective cohort studies [ 30 , 41 ] to identify patient and treatment supporter factors which may potentially influence mortality during TB treatment. In addition, operational research is needed to monitor the quality of treatment supervision and performance of DOT.…”

Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus‐associated tuberculosis

“…Tuberculosis (TB) is the leading cause of hospitalization and in‐hospital death in human immunodeficiency virus (HIV)‐infected people worldwide . In high‐burden settings hospitalized patients with HIV‐associated TB (HIV‐TB) have case fatality rates between 11 and 32% . The majority of these deaths occur within 2 weeks and in postmortem series inpatient HIV‐TB deaths are reported at a median of 4–5 days after admission, with 50% of deaths occurring in patients already on anti‐TB therapy …”

Factors associated with mortality of TB/HIV co-infected patients in Ethiopia

“…Most previous studies addressing TB related HIV deaths have focused only on assessing the relative contribution of TB to HIV related mortality. (7, 8) Also, most studies assessing TB burden among those with PLHIV used secondary data generated during routine service delivery, making disease burden quantification less reliable. (7–10).…”